Wedbush Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $30.00

Denali Therapeutics (NASDAQ:DNLI) had its target price decreased by Wedbush from $32.00 to $30.00 in a research report report published on Wednesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Denali Therapeutics’ Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.79) EPS and FY2029 earnings at $1.27 EPS.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald upgraded Denali Therapeutics from a “neutral” rating to an “overweight” rating in a report on Thursday, April 10th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Finally, Bank of America reduced their target price on Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $33.79.

Denali Therapeutics Stock Down 0.3 %

NASDAQ:DNLI opened at $14.39 on Wednesday. The firm has a market capitalization of $2.09 billion, a P/E ratio of -5.21 and a beta of 1.49. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a fifty day moving average of $14.27 and a 200 day moving average of $20.08.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same period in the prior year, the firm posted ($0.68) EPS. As a group, analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently bought and sold shares of the company. TD Asset Management Inc raised its holdings in Denali Therapeutics by 16.1% in the first quarter. TD Asset Management Inc now owns 308,580 shares of the company’s stock worth $4,195,000 after buying an additional 42,828 shares during the last quarter. Knights of Columbus Asset Advisors LLC raised its holdings in Denali Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock worth $548,000 after acquiring an additional 1,058 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Denali Therapeutics in the 1st quarter valued at approximately $254,000. Y Intercept Hong Kong Ltd boosted its stake in Denali Therapeutics by 52.2% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 54,813 shares of the company’s stock valued at $745,000 after purchasing an additional 18,807 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Denali Therapeutics by 8.1% in the 1st quarter. Victory Capital Management Inc. now owns 41,627 shares of the company’s stock worth $566,000 after purchasing an additional 3,119 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.